The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Feasibility study of cationic liposome-encapsulated paclitaxel in combination with paclitaxel followed by FEC as induction therapy in HER2-negative breast cancer.
Michail Ignatiadis
No relevant relationships to disclose
Marc Lemort
No relevant relationships to disclose
Celine Wilke
Employment or Leadership Position - Medigene
Marie-Catherine Vanderbeeken
No relevant relationships to disclose
Veronique D'hondt
No relevant relationships to disclose
Andrea Gombos
No relevant relationships to disclose
Evandro De Azambuja
No relevant relationships to disclose
Fabienne Lebrun
No relevant relationships to disclose
Lissandra Dal Lago
No relevant relationships to disclose
Marion Maetens
No relevant relationships to disclose
Lieveke Ameye
No relevant relationships to disclose
Isabelle Veys
No relevant relationships to disclose
Stefan Michiels
No relevant relationships to disclose
Marianne Paesmans
No relevant relationships to disclose
Denis Larsimont
No relevant relationships to disclose
Christos Sotiriou
No relevant relationships to disclose
Jean-Marie Nogaret
No relevant relationships to disclose
Martine J. Piccart-Gebhart
No relevant relationships to disclose
Ahmad Awada
No relevant relationships to disclose